Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.
NASA Goddard Space Flight Center's Dr. Jennifer Wiseman explains the Hubble Space Telescope's view of the Pillars of Creation ...
TransCode Therapeutics, Inc. a communiqué ses résultats financiers pour l'ensemble de l'exercice terminé le 31 décembre 2025.
How-To Geek on MSN
Don't throw away your old GPU: It's the secret to a better Plex server
I added an old GPU to my Plex server and it finally stopped buffering ...
TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has ...
"The financing agreement provides TransCode with financial flexibility and ensures that TransCode can maintain operational momentum as we conduct our Phase 2a trial for our lead clinical program, ...
TransCode Therapeutics Inc. stock grades by Barron's. View RNAZ fundamental and sentiment analysis powered by MarketGrader.
15/04 TransCode Therapeutics, Inc. publie ses résultats pour l'exercice clos le 31 décembre 2025 CI 03/03 TransCode Therapeutics, Inc. et Unleash Immuno Oncolytics, Inc. concluent un accord de licence ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced today it has entered into an exclusive, worldwide, royalty-free license agreement with Unleash Immuno Oncolytics, Inc. to develop three ...
TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer. BOSTON, March ...
The data describe a template-driven RIG-I agonist strategy to selectively activate retinoic acid-inducible gene I (RIG-I) signaling inside tumor cells by leveraging overexpressed oncogenic microRNAs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results